Many Medicare Part D plans cover Linzess, but out-of-pocket costs can vary because private insurance companies manage these plans. Linzess is an expensive medication with no generic alternatives ...
Stocktwits on MSN
Why did Ironwood Pharmaceuticals stock skyrocket today?
The outlook assumes net sales for Linzess will be between $1.125 billion and $1.175 billion in FY2026. ・U.S. FDA had approved ...
At the same time, Ironwood backed its 2025 outlook for adjusted Ebitda of more than $135 million on revenue of $290 million to $310 million. For the current year, Linzess sales are expected to come in ...
Expects full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million -- Ended Q4 2025 with greater than ...
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for ...
FDA has announced it has approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation in adults, according to a news release. Linzess ...
The U.S. Food and Drug Administration on Wednesday approved Linzess (linaclotide), developed by Ironwood Pharmaceuticals (IRWD) and AbbVie (ABBV), for children with irritable bowel syndrome with ...
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback